Omri Maayan1, Christopher Babu1, Miguel E Tusa Lavieri1, Jason Chua2, Paul J Christos2, Theodore H Schwartz3. 1. Weill Cornell Medical College, New York, NY, USA. 2. Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA. 3. Department of Neurological Surgery, Weill Cornell Medicine/New York Presbyterian Hospital, 525 East 68th St, Box #99, New York, NY, 10065, USA. schwarh@med.cornell.edu.
Abstract
PURPOSE: Postoperative surgical site infections (SSIs) constitute a significant source of morbidity for neurosurgical patients. Protocols that minimize postoperative wound infections are integral to improving outcomes and curtailing expenditures. The present study seeks to identify risk factors for infection and assess the efficacy of prophylactic betadine irrigation and vancomycin powder in addition to standard antibiotic irrigation. METHODS: We reviewed craniotomies performed by THS at Weill Cornell/New York Presbyterian Hospital to treat neuro-oncologic pathology. Patients were divided into three groups: group 1 - antibiotic irrigation, group 2 - antibiotic irrigation and betadine irrigation, group 3 - antibiotic irrigation, betadine irrigation, and vancomycin powder. SSI was confirmed with bacterial culture. Risk factor identification and assessment of treatment paradigms was performed using chi-square tests and univariate logistic regression. RESULTS: Among 1209 total patients, the 30- and 90-day SSI rates were 1.7% and 3.5%, respectively. Significant predictors of SSI included preoperative use of bevacizumab (OR 40.84; p < 0.0001), foreign body (OR 4.06; p < 0.0001), prior radiation (OR 2.20; p = 0.03), and prior operation/biopsy (OR 1.92; p = 0.04). Risk of infection was 2.1% in low-risk cases and 6.9% in high-risk cases. A significant, incremental decrement in SSIs was identified between the prophylaxis groups, although only among low-risk cases: group 1: 4.53%, group 2: 1.39%, group 3: 0.42% (p = 0.02). Neither vancomycin powder nor betadine significantly reduced the risk of SSI in patients with one or more risk factors. CONCLUSION: Vancomycin powder with betadine irrigation decreased SSI rates following neuro-oncologic cranial procedures in patients at low risk of infection (i.e., no preoperative risk factors).
PURPOSE: Postoperative surgical site infections (SSIs) constitute a significant source of morbidity for neurosurgical patients. Protocols that minimize postoperative wound infections are integral to improving outcomes and curtailing expenditures. The present study seeks to identify risk factors for infection and assess the efficacy of prophylactic betadine irrigation and vancomycin powder in addition to standard antibiotic irrigation. METHODS: We reviewed craniotomies performed by THS at Weill Cornell/New York Presbyterian Hospital to treat neuro-oncologic pathology. Patients were divided into three groups: group 1 - antibiotic irrigation, group 2 - antibiotic irrigation and betadine irrigation, group 3 - antibiotic irrigation, betadine irrigation, and vancomycin powder. SSI was confirmed with bacterial culture. Risk factor identification and assessment of treatment paradigms was performed using chi-square tests and univariate logistic regression. RESULTS: Among 1209 total patients, the 30- and 90-day SSI rates were 1.7% and 3.5%, respectively. Significant predictors of SSI included preoperative use of bevacizumab (OR 40.84; p < 0.0001), foreign body (OR 4.06; p < 0.0001), prior radiation (OR 2.20; p = 0.03), and prior operation/biopsy (OR 1.92; p = 0.04). Risk of infection was 2.1% in low-risk cases and 6.9% in high-risk cases. A significant, incremental decrement in SSIs was identified between the prophylaxis groups, although only among low-risk cases: group 1: 4.53%, group 2: 1.39%, group 3: 0.42% (p = 0.02). Neither vancomycin powder nor betadine significantly reduced the risk of SSI in patients with one or more risk factors. CONCLUSION: Vancomycin powder with betadine irrigation decreased SSI rates following neuro-oncologic cranial procedures in patients at low risk of infection (i.e., no preoperative risk factors).
Authors: George M Ghobrial; David W Cadotte; Kim Williams; Michael G Fehlings; James S Harrop Journal: Neurosurg Focus Date: 2015-10 Impact factor: 4.047
Authors: Aaron J Clark; Nicholas A Butowski; Susan M Chang; Michael D Prados; Jennifer Clarke; Mei-Yin C Polley; Michael E Sughrue; Michael W McDermott; Andrew T Parsa; Mitchel S Berger; Manish K Aghi Journal: J Neurosurg Date: 2010-12-10 Impact factor: 5.115
Authors: Kalil G Abdullah; Mark A Attiah; Andrew S Olsen; Andrew Richardson; Timothy H Lucas Journal: J Neurosurg Date: 2015-06-19 Impact factor: 5.115
Authors: Ian A Buchanan; Daniel A Donoho; Arati Patel; Michelle Lin; Timothy Wen; Li Ding; Steven L Giannotta; William J Mack; Frank Attenello Journal: World Neurosurg Date: 2018-08-25 Impact factor: 2.104